<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML xmlns:st1 = "urn:schemas-microsoft-com:office:smarttags" xmlns:o = "urn:schemas-microsoft-com:office:office" XMLNS:U2 XMLNS:U1 XMLNS:U3 XMLNS:HR<U2 xmlns:v = "urn:schemas-microsoft-com:vml" xmlns:w = "urn:schemas-microsoft-com:office:word" XMLNS:U5 XMLNS:U7><HEAD><META http-equiv=Content-Type content="text/html; charset=US-ASCII"></HEAD>
<BODY id=role_body style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Arial" bottomMargin=7 leftMargin=7 topMargin=7 rightMargin=7><FONT id=role_document face=Arial color=#000000 size=2>
<DIV> </DIV>
<DIV> </DIV>
<DIV>
<BLOCKQUOTE style="PADDING-LEFT: 5px; MARGIN-LEFT: 5px; BORDER-LEFT: blue 2px solid">
<DIV style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial'">
<HR>
From: BlindguysRus1<BR>To: REPCODDS<BR>Sent: 4/27/2009 4:48:26 P.M. Pacific
Daylight Time<BR>Subj: Fwd: FW: Blind to be cured with stem cells<BR></DIV>
<DIV> </DIV><FONT style="BACKGROUND-COLOR: transparent" face=Arial color=#000000 size=2><FONT face=Arial color=#000000 size=2>
<DIV> </DIV>
<DIV> </DIV>
<DIV>
<BLOCKQUOTE style="PADDING-LEFT: 5px; MARGIN-LEFT: 5px; BORDER-LEFT: blue 2px solid">
<DIV style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial'">
<HR>
From: Samme.Ripley@ocfl.net<BR>Sent: 4/27/2009 11:54:36 A.M. Pacific
Daylight Time<BR>Subj: FW: Blind to be cured with stem cells<BR></DIV>
<DIV> </DIV><FONT style="BACKGROUND-COLOR: transparent" face=Arial color=#000000 size=2>
<DIV class=Section1>
<P class=MsoNormal><FONT face=Arial color=blue size=3><SPAN style="FONT-SIZE: 12pt; COLOR: blue; FONT-FAMILY: Arial">Sharing a new
treatment for the blind which has been discovered in the <st1:country-region w:st="on"><st1:place w:st="on">United
Kingdom</st1:place></st1:country-region> and soon put to the
test.<o:p></o:p></SPAN></FONT></P>
<P class=MsoNormal><FONT face=Arial color=blue size=3><SPAN style="FONT-SIZE: 12pt; COLOR: blue; FONT-FAMILY: Arial"><o:p> </o:p></SPAN></FONT></P>
<P class=MsoNormal><FONT face=Arial color=blue size=3><SPAN style="FONT-SIZE: 12pt; COLOR: blue; FONT-FAMILY: Arial">..smr<o:p></o:p></SPAN></FONT></P>
<P class=MsoNormal><FONT face=Arial color=blue size=3><SPAN style="FONT-SIZE: 12pt; COLOR: blue; FONT-FAMILY: Arial"><o:p> </o:p></SPAN></FONT></P>
<P class=MsoNormal><FONT face=Arial color=blue size=3><SPAN style="FONT-SIZE: 12pt; COLOR: blue; FONT-FAMILY: Arial"><o:p> </o:p></SPAN></FONT></P>
<P class=MsoNormal><FONT face=Arial color=blue size=3><SPAN style="FONT-SIZE: 12pt; COLOR: blue; FONT-FAMILY: Arial"><o:p> </o:p></SPAN></FONT></P>
<DIV>
<DIV class=MsoNormal style="TEXT-ALIGN: center" align=center><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt">
<HR tabIndex=-1 align=center width="100%" SIZE=2>
</SPAN></FONT></DIV>
<P class=MsoNormal><B><FONT face=Tahoma size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Tahoma">From:</SPAN></FONT></B><FONT face=Tahoma size=2><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Tahoma">
Disability Relations Group [mailto:<st1:PersonName w:st="on">drg@drgglobal.com</st1:PersonName>] <BR><B><SPAN style="FONT-WEIGHT: bold">Sent:</SPAN></B> Friday, April 24, 2009 3:49
PM<BR><B><SPAN style="FONT-WEIGHT: bold">To:</SPAN></B> <st1:PersonName w:st="on">Ripley, Samme</st1:PersonName><BR><B><SPAN style="FONT-WEIGHT: bold">Subject:</SPAN></B> Blind to be cured with stem
cells</SPAN></FONT><o:p></o:p></P></DIV>
<P class=MsoNormal><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt"><o:p> </o:p></SPAN></FONT></P>
<P style="MARGIN-RIGHT: 48.55pt"><FONT face=Arial size=3><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Arial"><IMG SRC="cid:X.MA1.1240928144@aol.com" height=116 width=713 border=0 DATASIZE="8043" ID="MA1.1240928144" ><o:p></o:p></SPAN></FONT></P>
<TABLE class=MsoNormalTable style="WIDTH: 606pt" cellSpacing=0 cellPadding=0 width=808 border=0>
<TBODY>
<TR style="HEIGHT: 45pt" height=60>
<TD style="PADDING-RIGHT: 3.75pt; PADDING-LEFT: 3.75pt; BACKGROUND: #003366; PADDING-BOTTOM: 3.75pt; WIDTH: 100%; PADDING-TOP: 3.75pt; HEIGHT: 45pt" width="100%" bgColor=#003366 height=60>
<TABLE class=MsoNormalTable style="WIDTH: 100%" cellSpacing=0 cellPadding=0 border=0>
<TBODY>
<TR>
<TD style="PADDING-RIGHT: 3.75pt; PADDING-LEFT: 3.75pt; PADDING-BOTTOM: 3.75pt; PADDING-TOP: 3.75pt">
<P style="TEXT-ALIGN: center" align=center><FONT face="Trebuchet MS" color=white size=5><SPAN style="FONT-SIZE: 18pt; COLOR: white; FONT-FAMILY: 'Trebuchet MS'"><BR></SPAN></FONT><FONT face="Trebuchet MS" color=white size=6><SPAN style="FONT-SIZE: 24pt; COLOR: white; FONT-FAMILY: 'Trebuchet MS'">Blind
to be cured with stem cells</SPAN></FONT><FONT face="Trebuchet MS" color=white size=5><SPAN style="FONT-SIZE: 18pt; COLOR: white; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P></TD>
<TD style="PADDING-RIGHT: 3.75pt; PADDING-LEFT: 3.75pt; PADDING-BOTTOM: 3.75pt; PADDING-TOP: 3.75pt">
<P class=MsoNormal style="TEXT-ALIGN: right" align=right><FONT face=Verdana color=white size=2><SPAN style="FONT-SIZE: 10pt; COLOR: white; FONT-FAMILY: Verdana"><o:p> </o:p></SPAN></FONT></P></TD></TR></TBODY></TABLE>
<P class=MsoNormal><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt"><o:p></o:p></SPAN></FONT></P></TD></TR>
<TR style="HEIGHT: 4.5pt" height=6>
<TD style="PADDING-RIGHT: 3.75pt; PADDING-LEFT: 3.75pt; BACKGROUND: #0066cc; PADDING-BOTTOM: 3.75pt; PADDING-TOP: 3.75pt; HEIGHT: 4.5pt" bgColor=#0066cc height=6>
<P class=MsoNormal><FONT face="Times New Roman" size=1><SPAN style="FONT-SIZE: 5pt"><o:p> </o:p></SPAN></FONT></P></TD></TR>
<TR>
<TD style="PADDING-RIGHT: 3.75pt; PADDING-LEFT: 3.75pt; BACKGROUND: white; PADDING-BOTTOM: 3.75pt; WIDTH: 100%; PADDING-TOP: 3.75pt" width="100%" bgColor=white>
<TABLE class=MsoNormalTable style="WIDTH: 100%" cellSpacing=0 cellPadding=0 border=0>
<TBODY>
<TR>
<TD style="PADDING-RIGHT: 3.75pt; PADDING-LEFT: 3.75pt; PADDING-BOTTOM: 3.75pt; PADDING-TOP: 3.75pt">
<P class=MsoNormal style="MARGIN-BOTTOM: 4.5pt; TEXT-ALIGN: center" align=center><B><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"> <o:p></o:p></SPAN></FONT></B></P><!-- BEGIN: Heading -->
<DIV id=region-print-friendly>
<DIV>
<DIV>
<P class=MsoNormal><B><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><!-- END: Heading --><!-- Article Content --></SPAN></FONT></B><SPAN class=small><FONT face="Trebuchet MS" color=black size=4><!-- BEGIN: Module - Advert:Top --><!-- For Travel Search --><!--SECTION:parameter parameter="dart.server" /--><!-- END: Module - Advert:Top --><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'"><!-- BEGIN: Module - Main Heading -->From
</SPAN></FONT></SPAN><SPAN class=byline><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">The
Sunday Times</SPAN></FONT></SPAN><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P></DIV>
<DIV>
<P class=MsoNormal><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">April
19, 2009</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P></DIV>
<H1><B><FONT face="Trebuchet MS" color=black size=6><SPAN style="FONT-SIZE: 24pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Blind
to be cured with stem cells</SPAN></FONT></B><FONT face="Trebuchet MS" color=#0066cc><SPAN style="COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></H1><!-- END: Module - Main Heading --><!--CMA user Call Diffrenet Variation Of Image --><!-- BEGIN: Module - M24 Article Headline with no image (a) --><!-- getting the section url from article. This has been done so that correct url is
generated if we are coming from a section or topic --><!-- Print Author name associated with the article --><!-- Print Author name from By Line associated with the article -->
<DIV id=main-article>
<DIV>
<P class=MsoNormal><SPAN class=byline><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Sarah-Kate
Templeton, Health Editor </SPAN></FONT></SPAN><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P></DIV></DIV><!-- END: Module - M24 Article Headline with no image --><!-- BEGIN: Module - Main Article --><!-- Check the Article Type and display accordingly--><!-- Print Author image associated with the Author--><!-- Print the body of the article--><!-- Pagination -->
<DIV id=related-article-links>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">BRITISH
scientists have developed the world's first stem cell therapy to
cure the most common cause of blindness. Surgeons predict it
will become a routine, one-hour procedure that will be generally
available in six or seven years' time. </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">The
treatment involves replacing a layer of degenerated cells with
new ones created from embryonic stem cells. It was pioneered by
scientists and surgeons from the <st1:place w:st="on"><st1:PlaceType w:st="on">Institute</st1:PlaceType> of
<st1:PlaceName w:st="on">Ophthalmology</st1:PlaceName></st1:place> at
University College London and Moorfields eye hospital.
</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">This
week Pfizer, the world's largest pharmaceutical research
company, will announce its financial backing to bring the
therapy to patients. </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">The
treatment will tackle age-related macular degeneration (AMD),
the most common cause of blindness. It affects more than 500,000
Britons and the number is forecast to increase significantly as
people live longer. The disease involves the loss of eye cells.
</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Under
the new treatment, embryonic stem cells are transformed into
replicas of the missing cells. They are then placed on an
artificial membrane which is inserted in the back of the retina.
</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Tom
Bremridge, chief executive of the Macular Disease Society, said:
"This is a huge step forward for patients. We are extremely
pleased that the big guns have become involved, because, once
this treatment is validated, it will be made available to a huge
volume of patients." </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Embryonic
stem cells have the ability to develop into all types of body
tissue. Their use is controversial, however, because it involves
the destruction of human embryos. </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Laboratory
trials completed by the British team have demonstrated that stem
cells can prevent blindness in rats with a similar disease to
AMD. They have also successfully tested elements of the
technology in pigs. </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">The
team is led by Professor Pete Coffey, director of the London
Project to Cure Blindness, working alongside Lyndon da Cruz, a
surgeon at Moorfields. </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Coffey
said the treatment would take "less than an hour, so it really
could be considered as an outpatient procedure. We are trying to
get it out as a common therapy". </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">He
welcomed Pfizer's agreement to manufacture the membranes,
saying: "This is a major development because of the size of the
partner. We need a big pharmaceutical company to scale it up.
</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">"We
have nearly 14m people within <st1:place w:st="on">Europe</st1:place> with AMD. This will ensure that the
therapy gets through to clinical trials in a safe and effective
manner." </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Professor
Peng Khaw, director of the Biomedical Research Centre at
Moorfields and the UCL Institute of Ophthalmology, added: "This
shows that stem cell therapy is coming of age. It offers great
hope for many sufferers around the world who cannot be treated
with conventional treatment." He added: "All my patients say to
me is, 'When will this stem cell treatment be ready? I want it
now'." </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Pfizer's
role would be crucial in bringing production of the membranes to
an industrial level. </SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">The
team is applying for regulatory approval for trials from the
Medicines and Healthcare products Regulatory Agency, the Human
Tissue Authority and the gene therapy advisory committee.
</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">The
clinical trial, due within two years, is expected to be the
second in the world to use embryonic stem cells on humans. The
first, on patients with spinal cord injuries, will start this
year in <st1:country-region w:st="on"><st1:place w:st="on">America</st1:place></st1:country-region>.
</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P></DIV></DIV>
<DIV>
<DIV>
<P class=x-smallcolor-666><FONT face="Trebuchet MS" color=black size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: black; FONT-FAMILY: 'Trebuchet MS'">Copyright
2009 Times Newspapers Ltd.</SPAN></FONT><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"><o:p></o:p></SPAN></FONT></P>
<P><FONT face="Trebuchet MS" color=#0066cc size=4><SPAN style="FONT-SIZE: 13.5pt; COLOR: #0066cc; FONT-FAMILY: 'Trebuchet MS'"> <o:p></o:p></SPAN></FONT></P></DIV></DIV></DIV></TD></TR></TBODY></TABLE>
<P class=MsoNormal><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt"><o:p></o:p></SPAN></FONT></P></TD></TR></TBODY></TABLE>
<DIV class=MsoNormal style="TEXT-ALIGN: center" align=center><FONT face=Arial size=2><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">
<HR align=center width="87%" SIZE=3>
</SPAN></FONT></DIV>
<P style="MARGIN-RIGHT: 48.55pt"><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt"> This Disability Relations Group e-mail is
sponsored in part by:</SPAN><U2:P></U2:P></FONT><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN></FONT></P>
<P class=MsoNormal style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><B><U2:P></U2:P><FONT face="Times New Roman" size=3><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 12pt"> <o:p></o:p></SPAN></FONT></B></P>
<P class=MsoNormal style="TEXT-ALIGN: center; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto" align=center><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt"><IMG SRC="cid:X.MA2.1240928144@aol.com" onmousedown="" onmouseover="" onmouseout="" height=159 alt="Accessing Digital America" width=172 border=0 DATASIZE="13832" ID="MA2.1240928144" ><o:p></o:p></SPAN></FONT></P>
<P><FONT face=Arial color=black size=2><U2:P></U2:P><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Arial">Accessing Digital
America (ADA), the Catalyst for Digital Access, is surveying government Web
sites and shining a light on the good, the bad and the ugly. (re Section 508
compliance and the accessibility of their content to persons with
disabilities.) <o:p></o:p></SPAN></FONT></P>
<P><FONT face=Arial color=black size=2><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Arial">The Department of
Health and Human Services WebSites were among those
surveyed.<o:p></o:p></SPAN></FONT></P>
<P><FONT face=Arial color=black size=2><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Arial">"<st1:City w:st="on"><st1:place w:st="on">ADA</st1:place></st1:City> was right on in
their reviews of our sites," said Prudence Goforth, Director of Web
Communications and New Media Division in the HHS Office of the Assistant
Secretary for Public Affairs. We took their findings seriously and are
implementing a plan to make all HHS Web content accessible. Throughout, we
have had a positive relationship with <st1:City w:st="on"><st1:place w:st="on">ADA</st1:place></st1:City>." <o:p></o:p></SPAN></FONT></P>
<P><FONT face=Arial color=black size=2><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Arial">HHS has been a
model of how a Federal agency should respond to requests for access.
Unfortunately, <st1:City w:st="on"><st1:place w:st="on">ADA</st1:place></st1:City> can't say the same for others,
including the White House, who has not responded at all.
<o:p></o:p></SPAN></FONT></P><FONT face="Times New Roman" size=3><U2:P></U2:P></FONT>
<DIV class=MsoNormal style="TEXT-ALIGN: center" align=center><FONT face="Times New Roman" size=3><U1:IMAGEDATA src="/C:\DOCUME~1\Mike\LOCALS~1\Temp\msohtml1\01\clip_image004.png" u2:title="DRG"></U1:IMAGEDATA><U3:WRAP type="square"></U3:WRAP><SPAN style="FONT-SIZE: 12pt"><HR<U2:P><U1:SHAPE id=_x0000_s1026 style="MARGIN-TOP: 13.8pt; Z-INDEX: -1; LEFT: 0px; MARGIN-LEFT: 0px; WIDTH: 82.9pt; POSITION: absolute; HEIGHT: 148.25pt; TEXT-ALIGN: left; mso-position-horizontal: left; mso-position-horizontal-relative: text; mso-position-vertical: absolute; mso-position-vertical-relative: text" type="#_x0000_t75" wrapcoords="-107 0 -107 21540 21600 21540 21600 0 -107 0"></U1:SHAPE><U2:P></U2:P>size=3
width="84%" align=center> </SPAN></FONT></DIV>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; MARGIN-RIGHT: 48.55pt; TEXT-ALIGN: center; mso-margin-top-alt: 0in" align=center><v:shapetype id=_x0000_t75 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"><v:stroke joinstyle="miter"></v:stroke><v:formulas><v:f eqn="if lineDrawn pixelLineWidth 0"></v:f><v:f eqn="sum @0 1 0"></v:f><v:f eqn="sum 0 0 @1"></v:f><v:f eqn="prod @2 1 2"></v:f><v:f eqn="prod @3 21600 pixelWidth"></v:f><v:f eqn="prod @3 21600 pixelHeight"></v:f><v:f eqn="sum @0 0 1"></v:f><v:f eqn="prod @6 1 2"></v:f><v:f eqn="prod @7 21600 pixelWidth"></v:f><v:f eqn="sum @8 21600 0"></v:f><v:f eqn="prod @7 21600 pixelHeight"></v:f><v:f eqn="sum @10 21600 0"></v:f></v:formulas><v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"></v:path><o:lock v:ext="edit" aspectratio="t"></o:lock></v:shapetype><v:shape id=_x0000_s1026 style="MARGIN-TOP: 0px; Z-INDEX: 1; LEFT: 0px; MARGIN-LEFT: 0px; WIDTH: 486pt; POSITION: absolute; HEIGHT: 342.75pt; TEXT-ALIGN: left; mso-position-horizontal: left; mso-position-horizontal-relative: text; mso-position-vertical-relative: line; mso-wrap-distance-left: 0; mso-wrap-distance-top: 0; mso-wrap-distance-right: 0; mso-wrap-distance-bottom: 0" type="#_x0000_t75" alt="" o:allowoverlap="f"><v:imagedata src="cid:3000an$IN488012406025263@BLaptop" o:title="3000an$IN488012406025263@BLaptop"></v:imagedata><w:wrap type="square"></w:wrap></v:shape><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt"><U2:P></U2:P><U2:P></U2:P></SPAN></FONT><B><FONT face=Century size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century">Disability
Relations Group</SPAN></FONT></B><U2:P></U2:P><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; MARGIN-RIGHT: 48.55pt; TEXT-ALIGN: center; mso-margin-top-alt: 0in" align=center><st1:street u4:st="on"><st1:street u4:st="on"><st1:street u4:st="on"><st1:street u4:st="on"><st1:address style="BACKGROUND-POSITION: left bottom; BACKGROUND-IMAGE: url(res://ietag.dll/#34/#1001); BACKGROUND-REPEAT: repeat-x" tabIndex=0 u4:st="on"><st1:Street w:st="on"><st1:address w:st="on"><B><FONT face=Century size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century">12552
Belcher Rd.
S.</SPAN></FONT></B></st1:address></st1:Street></st1:address></st1:street></st1:street></st1:street></st1:street><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><U2:P></U2:P><o:p></o:p></SPAN></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; MARGIN-RIGHT: 48.55pt; TEXT-ALIGN: center; mso-margin-top-alt: 0in" align=center><st1:city u4:st="on"><st1:city u4:st="on"><st1:city u4:st="on"><st1:city u4:st="on"><st1:place u4:st="on"><st1:City w:st="on"><st1:place w:st="on"><B><FONT face=Century size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century">Largo</st1:place></st1:City></SPAN></FONT></B></st1:place></st1:city></st1:city></st1:city></st1:city><B><FONT face=Century size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century">, FL
33773<U2:P></U2:P></SPAN></FONT></B><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; MARGIN-RIGHT: 48.55pt; TEXT-ALIGN: center; mso-margin-top-alt: 0in" align=center><B><FONT face=Century size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century">Voice:727-531-1000</SPAN></FONT></B><U2:P></U2:P><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; MARGIN-RIGHT: 48.55pt; TEXT-ALIGN: center; mso-margin-top-alt: 0in" align=center><B><FONT face=Century size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century">Fax:
727-539-7588</SPAN></FONT></B><U2:P></U2:P><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; MARGIN-RIGHT: 48.55pt; TEXT-ALIGN: center; mso-margin-top-alt: 0in" align=center><B><FONT face=Century size=2><U2:P></U2:P><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century">We are on
the Web!! Come visit us at:</SPAN></FONT></B><U2:P></U2:P><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; MARGIN-RIGHT: 48.55pt; TEXT-ALIGN: center; mso-margin-top-alt: 0in" align=center><B><U><FONT face=Century size=2><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Century"><A title=http://www.drgglobal.com/ href="http://www.drgglobal.com/">www.drgglobal.com</A></SPAN></FONT></U></B><U2:P></U2:P><FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN></FONT></P>
<P style="MARGIN-RIGHT: 48.55pt"><FONT face="Times New Roman" size=2><SPAN style="FONT-SIZE: 10pt"> </SPAN></FONT>Disability Relations Group is a
global disability relations image and policy facilitation firm. Its clients
range from small community nonprofits to Fortune 500s all wishing to better
their relations with the disabled and elder communities. It works not only
in the areas concerning general issues related to disability and elder
concerns, but also specializes in the areas of accessible voting, technology
and transportation.<FONT face=Arial><SPAN style="FONT-FAMILY: Arial"><o:p></o:p></SPAN><U2:P></U2:P></FONT></P>
<DIV class=MsoNormal style="TEXT-ALIGN: center" align=center><FONT face="Times New Roman" size=2><SPAN style="FONT-SIZE: 10pt">
<HR align=center width="100%" SIZE=2>
</SPAN></FONT></DIV>
<P class=MsoNormal style="MARGIN-RIGHT: 48.55pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><B><st1:city u3:st="on"><FONT face="Times New Roman" size=3><U2:P></U2:P><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 12pt">Important
Note</SPAN></FONT></B><U2:P></U2:P><o:p></o:p></P>
<P class=MsoNormal style="MARGIN-RIGHT: 48.55pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><FONT face=Arial size=2><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">The
above information is provided as a service and is not necessarily the
opinion of Disability Relations Group its management, members, sponsors or
clients. If you have questions, concerns or problems with this e-mail please
contact <A title=mailto:nicoler@drgglobal.com href="mailto:nicoler@drgglobal.com">nicoler@drgglobal.com</A>
</SPAN></FONT><U2:P></U2:P><o:p></o:p></P><FONT face="Times New Roman" size=3><U2:P></U2:P></FONT>
<DIV class=MsoNormal style="TEXT-ALIGN: center" align=center><FONT face="Times New Roman" size=3><SPAN style="FONT-SIZE: 12pt">
<HR align=center width="100%" SIZE=2>
</SPAN></FONT></DIV>
<P class=MsoNormal style="LINE-HEIGHT: 15pt; MARGIN-RIGHT: 48.55pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><B><FONT face=Arial color=black size=2><U2:P></U2:P><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Arial">Unsubscribe
information:</SPAN></FONT></B><U2:P></U2:P><o:p></o:p></P>
<P class=MsoNormal style="MARGIN-RIGHT: 48.55pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto"><FONT face=Arial size=2><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial">If you
would like to be removed from future mailings please send e-mail to <A title=mailto:drg@drgglobal.com href="mailto:drg@drgglobal.com">drg@drgglobal.com</A> and type REMOVE in the
subject line Please do not reply to this e-mail as we are unable to respond
to messages sent to this address or write us at <st1:street u3:st="on"><U5:ADDRESS style="BACKGROUND-POSITION: left bottom; BACKGROUND-IMAGE: url(res://ietag.dll/#34/#1001); BACKGROUND-REPEAT: repeat-x" tabIndex=0 u6:st="on"><U5:STREET u6:st="on">12552 Belcher Rd.
S.</U5:STREET></U5:ADDRESS></st1:street>, <st1:city u3:st="on"><U7:CITY u8:st="on"><st1:city u4:st="on">Largo</U7:CITY></st1:city></st1:city> , Fl
33773.
<U2:P></U2:P></SPAN></FONT><o:p></o:p></P></DIV><U2:P></U2:P></st1:city>
<TABLE>
<TBODY>
<TR>
<TD bgColor=#ffffff><FONT color=#000000><PRE>_____________________________________________________________________
PLEASE NOTE: Florida has a very broad public records law (F. S. 119).
All e-mails to and from County Officials are kept as a public record.
Your e-mail communications, including your e-mail address may be
disclosed to the public and media at any time.</PRE></FONT></TD></TR></TBODY></TABLE></HR<U2:P></FONT></BLOCKQUOTE></DIV></FONT><BR><FONT style="FONT: 10pt arial,san-serif; COLOR: black">
<HR style="MARGIN-TOP: 10px">
<B>A Good Credit Score is 700 or Above. <A title=http://pr.atwola.com/promoclk/100126575x1220572846x1201387511/aol?redir=http://www.freecreditreport.com/pm/default.aspx?sc=668072&hmpgID=62&bcd=Aprilfooter427NO62 href="http://pr.atwola.com/promoclk/100126575x1220572846x1201387511/aol?redir=http://www.freecreditreport.com/pm/default.aspx?sc=668072&hmpgID=62&bcd=Aprilfooter427NO62">See
yours in just 2 easy
steps!</A></B></FONT></FONT></BLOCKQUOTE></DIV></FONT><br/><font style="color:black;font:normal 10pt arial,san-serif;"> <hr style="margin-top:10px"/>Access 350+ FREE radio stations anytime from anywhere on the web. <a href="http://toolbar.aol.com/aolradio/download.html?ncid=emlcntusdown00000003">Get the Radio Toolbar</a>!</font></DIV></BODY></HTML>